Novavax Inc. (NASDAQ: NVAX) is soaring on news that its experimental H1N1 swine flu vaccine was trenchant in animal tests. The vaccine won’t be approved nor ready for advertizement ingest in humans for two years. At 8:53 AM EST we have already seen over 650,000 shares trade hands and th last print has the stock up 10.5% at $4.96. The 52-week high is $5.59 and cipher intensity is now over 6 million shares now that swine flu is such a buzz-word for traders. -JON OGG
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment